MiMedx Group (NASDAQ:MDXG – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Insider and Institutional Ownership
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares MiMedx Group and Absci”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiMedx Group | $418.63 million | 1.37 | $48.58 million | $0.32 | 12.06 |
| Absci | $2.80 million | 150.83 | -$115.18 million | ($0.85) | -3.25 |
MiMedx Group has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for MiMedx Group and Absci, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiMedx Group | 0 | 1 | 5 | 0 | 2.83 |
| Absci | 1 | 1 | 4 | 0 | 2.50 |
MiMedx Group currently has a consensus target price of $9.60, indicating a potential upside of 148.70%. Absci has a consensus target price of $7.08, indicating a potential upside of 156.52%. Given Absci’s higher possible upside, analysts clearly believe Absci is more favorable than MiMedx Group.
Profitability
This table compares MiMedx Group and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiMedx Group | 11.60% | 29.37% | 21.97% |
| Absci | -4,113.68% | -62.33% | -53.24% |
Risk and Volatility
MiMedx Group has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.
Summary
MiMedx Group beats Absci on 10 of the 14 factors compared between the two stocks.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
